Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 6/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882478 | 1.00 | MAOB (0.42) | MAOBERN1PDE4AIGF1RPDE4B | |
| SCHEMBL2882477 | 1.00 | MAOB (0.42) | MAOBERN1PDE4AIGF1RPDE4B | |
| SCHEMBL5734765 | 0.91 | CYP11B1 (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5734770 | 0.91 | CYP11B1 (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL5734763 | 0.91 | CYP11B1 (0.39) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2888178 | 0.87 | PDE4A (0.44) | PDE4AIGF1RPDE4BPDE4CPDE4D | |
| SCHEMBL2888181 | 0.87 | PDE4A (0.44) | PDE4AIGF1RPDE4BPDE4CPDE4D | |
| SCHEMBL5743705 | 0.87 | PDE4A (0.44) | PDE4AIGF1RPDE4BPDE4CPDE4D | |
| SCHEMBL2888763 | 0.87 | PDE4D (0.38) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL2888767 | 0.87 | PDE4D (0.38) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776893-B2 | Use of PDE4 inhibitors for the treatment of diabetes mellitus | NYCOMED GMBH (DE) | 2010-08-17 | — | — | US | disclosed |
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | ALTANA PHARMA AG (DE) | 2006-12-14 | — | — | US | disclosed |
| EP-1650193-A2 | 6-Phenylphenanthridines with PDE-IV inhibiting activity | ALTANA Pharma AG (DE) | 2006-04-26 | — | — | EP | disclosed |
| EP-1147089-B1 | PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY | ALTANA PHARMA AG (DE) | 2005-12-07 | — | — | EP | disclosed |
| WO-2005023253-A1 | USE OF PDE4 INHIBITORS FOR THE TREATMENT OF DIABETES MELLITUS | ALTANA PHARMA AG (DE) | 2005-03-17 | — | — | WO | disclosed |
| US-6476025-B1 | Phenylphennanthridines with PDE-IV inhibiting activity | ALTANA PHARMA AG (DE) | 2002-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281745-A1 | Use of pde4 inhibitors for the treatment of diabetes mellitus | PDE4A, PDE4B, PDE12 | MAOB 1299/4885ERN1 1241/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.